Peptide Decoding
New?New to peptides?Start here →
Decoding

B7-33_Dosage, benefits & legal status

Also known as relaxin B-chain analog, B7 33, single-chain relaxin

Published August 24, 2026

A single-chain piece of relaxin, built to keep the anti-scarring effect and drop the tumor risk.

Recovery / nerveRelaxin analogResearch only
Common vial size10 mg
DoseResearch only
FrequencyVaries
RouteUnder the skin (subcutaneous)
StatusResearch only
CycledNo established pattern

Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.

See how this dose compares across the library →

01

What is B7-33?

Plain language first. The technical label stays, but it never stands alone.

Overview

A short piece of a hormone called relaxin, designed to keep its anti-scarring effect without the part linked to tumor growth. It has never been tested in a person.

The technical version

A 26-residue single-chain derivative of the H2 relaxin B-chain, functioning as a biased RXFP1 agonist favouring pERK1/2 over cAMP signaling. Developed at the Florey Institute in 2016. Reported to promote MMP-2 expression and reverse fibrosis across multiple rodent organ models. In vitro serum half-life approximately 6 minutes.

What it's used for

Studied in animals for scarring in the heart, lungs and kidneys. Sold online for recovery and tissue repair on the strength of that animal work.

02

How does B7-33 work?

What it does in the body, and where.

Relaxin does two things through the same receptor, and B7-33 was built to keep one of them.

  1. 01
    Relaxin activates RXFP1 through two routes
    One route runs through cAMP and one through pERK1/2. The anti-scarring effect is attributed to the second.
  2. 02
    B7-33 leans toward one and away from the other
    It is described as a biased agonist, favouring the pERK pathway with much less cAMP activation. That bias is the entire design intention.
  3. 03
    The reason for the bias is a tumor concern
    Strong cAMP activation by full relaxin has been linked to tumor growth in long-term use, and to increased cardiac workload. Dropping that arm is the point of the molecule.
  4. 04
    It clears extremely fast
    Serum half-life is reported at around six minutes in laboratory testing, which is short even by peptide standards. Later work attaching a fatty acid extended it to around sixty minutes.
03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Reducing scarring in the heart after injury, in animal modelsEarly research
  • Kidney and lung fibrosis, in animal modelsEarly research
  • Widening blood vessels and improving blood flow, in animal modelsEarly research

The published record

Research index

11

Papers and trials about B7-33

6 papers tagged human · 5 not reviews or lab · 0 clinical trial publications

Furthest stage reached: No clinical trial on record

Compare this against the whole library →

In animals9
In the lab1
Reviews1
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.

B7-33 vial rendering
Compound field notes

At a glance

Four things to know about B7-33

01

Evidence

Research only

02

Category

Healing and recovery

03

Common vial

10 mg

04

Half-life

About 6 minutes in serum

04

How much, and do you cycle it?

The range, and whether you take breaks.

Research only, varies. No established pattern No range

No published human study establishes a schedule.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

About 6 minutes in serumpeer-reviewed

Measured in human serum in vitro rather than in a person. A fatty-acid conjugated version was reported to extend this to about 60 minutes. Neither figure is a human pharmacokinetic result.

Source: Reported in structure-activity work from the originating laboratory

You can compare this against the whole library to see where it sits.

06

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)
Printed on the vial.
What you paid per vial
$
Used for cost per dose only.
Your dose (mcg)
Commonly referenced range: 100 up to 500 mcgCommunity practice

Choose your mix

your own mL
units · —
Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

YOUR DRAW3.3 / 100 units
3.3 units is a very small line to read, so a small slip is a large error.
What it costs

B7-33 starts at $60.00 across 6 vendors, typically $7.00 – $13.20 per mg.

6 listings, last read Oct 10, 2026. Shipping and card fees are not included.

See all 6 listings →
07

How do you store it?

Before mixing, and after.

Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.

Unmixed lyophilized B7-33 keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Who should avoid it

Check these before anything else.
  • Pregnancy or breastfeeding
  • Any active cancer, since the parent hormone has a tumour-growth signal
  • Any use, given no human trial exists

Stop and get help

These are emergencies. Seek care.
  • Any allergic reaction
  • Any unexpected symptom

Common effects

Expected, and usually mild.
  • No human safety data exists.
  • Everything known comes from cell work and animal models.

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is B7-33 approved?

And where the numbers on this page come from.

No. B7-33 is not approved for any use, anywhere. It is sold labeled for laboratory research only, and there is no legal route to buy it for human use.

  • Approval status
    Research only
  • Route
    Under the skin (subcutaneous)
  • Checked
    24 August 2026
  • Dose
    From community reports. No regulator or trial established this dose.
  • Vial size
    From what vendors typically list; not a recommendation.
  • Sources
    None traced yet.

What has happened recently

We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.

Guides for this compound

Sources

No primary source has been traced for this compound yet. Treat everything on this page as unverified until one is. How we grade evidence

Beyond these, 11 records are indexed. Browse the records